RxDoctor Payments Data

Rohit Moudgil, MD

Cardiovascular Disease · Cleveland, OHNPI 1952844904

Payments from drug & device makers

$2,310in general payments, 2019–2025

Across 15 payments — averaging $153.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$940
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$654
  • Medtronic$269
  • Pfizer$157
  • Novartis$124
  • Sumitomo Pharma America, Inc.$84
  • plus $82 from 1 others

What the payments were for

  • Consulting fees$94041%
  • Speaking & faculty fees$50022%
  • Food & beverage$87038%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,310 in reported general payments places this provider in the 55th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$126,728
Medicare patients
3,903
Services billed
5,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban225$252,836
EntrestoSacubitril/Valsartan98$159,737
JardianceEmpagliflozin97$121,364
Repatha SureclickEvolocumab11$8,029
Metoprolol Succinate338$5,564
Rosuvastatin Calcium196$3,482
Atorvastatin Calcium212$2,880
Nifedipine ErNifedipine105$2,531
Carvedilol299$2,352
Valsartan58$1,793
Chlorthalidone88$1,690
Ranolazine ErRanolazine13$1,410
Amiodarone Hcl46$1,349
Diltiazem 24hr Er (Cd)Diltiazem Hcl23$1,209
Clonidine12$1,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$157$252,836225 claims
NovartisEntresto$124$159,73798 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →